ArticleScience translational medicine2021
Epitope spreading toward wild-type melanocyte-lineage antigens rescues suboptimal immune checkpoint blockade responses.
Open access · greenAbstract read
In one paragraph
Article in Science translational medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers.
0numbers the graph read from it
0cells of the map it votes in
66citing papers in PubMed
6.3field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
66 citing papers in PubMed, 96 citations in OpenAlex.
- Immunopeptidomics-Guided Warehouse Design for Peptide-Based Immunotherapy in Chronic Lymphocytic Leukemia.Frontiers in immunology · 2021Trial
- The Dendritic Cell-based Vaccine PROTEXI leverages Antiviral CD4 T cell Memory to boost anti-tumor immune responses in mice.Nature communications · 2026Article
- Vitiligo as a Failure of Immune Resolution and Tissue Regeneration: From Stress Signals to Targeted Immune Modulation.Clinical reviews in allergy & immunology · 2026Review
- Novel insights into extracellular vesicles: An update on biomolecules, immunomodulation and clinical strategies in skin melanoma.Clinical and translational medicine · 2026Review
- Neutrophil Antigen Presentation Reprograms the Tumor Microenvironment and Elicits Durable and Broad Antitumor Immunity.Cancer research communications · 2026Article
- Risk Factors and Biomarkers for Immune Checkpoint Inhibitor-mediated Hepatotoxicity: Emerging Insights and Future Perspectives.Journal of clinical and translational hepatology · 2026Review
- Review
- Type 2 immunity links eczematous and lichenoid eruptions caused by immune checkpoint inhibitors.Journal of the American Academy of Dermatology · 2025Article
- CRATER tumor niches facilitate CD8Cell · 2025Article
- Preclinical models of melanoma leptomeningeal disease to assess intrathecal checkpoint blockade.Scientific reports · 2025Article
- Cancer Risk in Vitiligo: No Evidence of Increased Prevalence-A Systematic Review and Meta-analysis.Dermatology and therapy · 2025Article
- Association Between Immune-Related Adverse Events and Treatment Outcomes in Advanced Gastric Cancer Patients Receiving Nivolumab Plus Chemotherapy: A Retrospective Study.Cancer medicine · 2025Article
- Tumor antigens preferentially derive from unmutated genomic sequences in melanoma and non-small cell lung cancer.Nature cancer · 2025Article
- Immune checkpoint inhibition perturbs neuro-immune homeostasis and impairs cognitive function.Journal of experimental & clinical cancer research : CR · 2025Article
- Targeted STING Activation Using Modified Ultrasound-Responsive Microbubbles Enhances Immune Checkpoint Blockade Against Melanoma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Cancer immune evasion, immunoediting and intratumour heterogeneity.Nature reviews. Immunology · 2025Review
- Strategies to overcome tumour relapse caused by antigen escape after CAR T therapy.Molecular cancer · 2025Review
- DHODH modulates immune evasion of cancer cells via CDP-Choline dependent regulation of phospholipid metabolism and ferroptosis.Nature communications · 2025Article
- FAK inhibition combined with the RAF-MEK clamp avutometinib overcomes resistance to targeted and immune therapies in BRAF V600E melanoma.Cancer cell · 2025Article
- Immune-Mediated Liver Injury From Checkpoint Inhibitor: An Evolving Frontier With Emerging Challenges.Liver international : official journal of the International Association for the Study of the Liver · 2025Review
6 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
37 authors at 8 institutions in 4 countries.
Jennifer A LoCutaneous Biology Research Center, Department of Dermatology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.ORCID 0000-0002-9520-6874
Masayoshi KawakuboCutaneous Biology Research Center, Department of Dermatology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
Vikram R JunejaDepartment of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA 02115, USA.
Mack Y SuCutaneous Biology Research Center, Department of Dermatology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
Tal H ErlichCutaneous Biology Research Center, Department of Dermatology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.ORCID 0000-0003-0601-2574
Martin W LaFleurDepartment of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0002-5017-774X
Lajos V KemenyCutaneous Biology Research Center, Department of Dermatology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.ORCID 0000-0002-8233-1844
Mamunur RashidExperimental Cancer Genetics, Wellcome Trust Genome Campus, Hinxton, Cambridge CB10 1HH, UK.ORCID 0000-0001-9321-0469
Mohsen MalehmirDivision of Surgical Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.ORCID 0000-0001-6915-5850
S Alireza RabiDivision of Surgical Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
Rumya RaghavanBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Jennifer AlloucheCutaneous Biology Research Center, Department of Dermatology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.ORCID 0000-0002-2379-0979
Gyulnara KasumovaDivision of Surgical Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
Dennie T FrederickDivision of Surgical Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
Kristen E PaukenDepartment of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0002-4309-7880
Qing Yu WengCutaneous Biology Research Center, Department of Dermatology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.ORCID 0000-0002-4678-2664
Marcelo Pereira da SilvaCutaneous Biology Research Center, Department of Dermatology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.ORCID 0000-0002-8522-8834
Yu XuDepartment of Bioengineering, Stanford University, Stanford, CA 94305, USA.
Anita A J van der SandeCutaneous Biology Research Center, Department of Dermatology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
Whitney SilkworthCutaneous Biology Research Center, Department of Dermatology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.ORCID 0000-0002-7897-4652
Elisabeth RoiderCutaneous Biology Research Center, Department of Dermatology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
Edward P BrowneDepartment of Medicine, UNC-Chapel Hill, Chapel Hill, NC 27599, USA.ORCID 0000-0001-9070-7015
David J LiebBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.ORCID 0000-0001-7459-4719
Belinda WangBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.ORCID 0000-0001-5563-894X
Levi A GarrawayBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Catherine J WuBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.ORCID 0000-0002-3348-5054
Keith T FlahertyMassachusetts General Hospital Cancer Center, Boston, MA 02114, USA.ORCID 0000-0002-3402-0478
Constance E BrinckerhoffDepartments of Medicine and Biochemistry, Geisel School of Medicine at Dartmouth, Hanover, NH 03755, USA.
David W MullinsDepartments of Medical Education and Microbiology/Immunology, Geisel School of Medicine at Dartmouth, Hanover, NH 03755, USA.
David J AdamsExperimental Cancer Genetics, Wellcome Trust Genome Campus, Hinxton, Cambridge CB10 1HH, UK.
Nir HacohenMassachusetts General Hospital Cancer Center, Boston, MA 02114, USA.ORCID 0000-0002-2349-2656
Mai P HoangDepartment of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.ORCID 0000-0002-1406-7981
Genevieve M BolandDivision of Surgical Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA. dfisher3@partners.org dmanstein@mgh.harvard.edu arlene_sharpe@hms.harvard.edu gordon_freeman@dfci.harvard.edu gmboland@partners.org.ORCID 0000-0002-7522-6173
Gordon J FreemanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA. dfisher3@partners.org dmanstein@mgh.harvard.edu arlene_sharpe@hms.harvard.edu gordon_freeman@dfci.harvard.edu gmboland@partners.org.ORCID 0000-0002-7210-5616
Arlene H SharpeDepartment of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA 02115, USA. dfisher3@partners.org dmanstein@mgh.harvard.edu arlene_sharpe@hms.harvard.edu gordon_freeman@dfci.harvard.edu gmboland@partners.org.ORCID 0000-0002-9736-2109
Dieter MansteinCutaneous Biology Research Center, Department of Dermatology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA. dfisher3@partners.org dmanstein@mgh.harvard.edu arlene_sharpe@hms.harvard.edu gordon_freeman@dfci.harvard.edu gmboland@partners.org.ORCID 0000-0002-4508-045X
David E FisherCutaneous Biology Research Center, Department of Dermatology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA. dfisher3@partners.org dmanstein@mgh.harvard.edu arlene_sharpe@hms.harvard.edu gordon_freeman@dfci.harvard.edu gmboland@partners.org.ORCID 0000-0002-5506-0575
Harvard University · USBroad Institute · USBrigham and Women's Hospital · USDartmouth College · USWellcome Sanger Institute · GBMassachusetts General Hospital · USStanford University · USUniversity of North Carolina Health Care · US
Funding
VectorP30CA006516 · NCI · DANA-FARBER CANCER INSTITUTE · PI Irene M. Ghobrial · 1985 to 2026
$330.6MTreating the P13-Kinase/AKTP50CA101942 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI David McDermott · 2003 to 2026
$53.4MMedical Scientist Training ProgramT32GM007753 · NIGMS · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI WALENSKY, LOREN DAVID · 1985 to 2021
$50.0MTransgenic/KnockoutP01AI056299 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI BLAZAR, BRUCE R · 2003 to 2023
$42.5MTranscriptional mechanisms and melanomaP01CA163222 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI DAVID E FISHER · 2013 to 2026
$25.3MTargeting SYK Kinase in AMLP50CA206963 · NCI · DANA-FARBER CANCER INST · PI GRAUBERT, TIMOTHY A · 2017 to 2021
$10.6MPersonal tumor neoantigens for immunity against chronic lymphocytic leukemiaR01CA155010 · NCI · DANA-FARBER CANCER INST · PI Catherine Ju-Ying Wu · 2011 to 2026
$9.6MThe MITF transcriptional network: melanoma risk and carcinogenesisR01AR043369 · NIAMS · MASSACHUSETTS GENERAL HOSPITAL · PI DAVID E FISHER · 1996 to 2026
$9.4MTherapeutic strategies for treatment of giant congenital melanocytic neviR01AR072304 · NIAMS · MASSACHUSETTS GENERAL HOSPITAL · PI DAVID E FISHER · 2017 to 2026
$3.9MCancer Immunology Training GrantT32CA207021 · NCI · DANA-FARBER CANCER INST · PI WUCHERPFENNIG, KAI W · 2016 to 2020
$2.4MA druggable dependency in low-MITF/high-AXL melanoma: preclinical efficacy and mechanism of action in a key treatment-resistant subclass.R01CA222871 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI FISHER, DAVID E · 2018 to 2022
$1.8MThe roles of UV, neoantigens, and epitope spreading in vitiligo and melanomaF30ES025626 · NIEHS · HARVARD MEDICAL SCHOOL · PI LO, JENNIFER A · 2015 to 2016
$94kNCI NIH HHS P01 CA163222NCI NIH HHS P30 CA006516NCI NIH HHS P50 CA101942NCI NIH HHS P50 CA206963NCI NIH HHS R01 CA155010NCI NIH HHS R01 CA222871NCI NIH HHS T32 CA207021NIAID NIH HHS P01 AI056299NIAMS NIH HHS R01 AR043369NIAMS NIH HHS R01 AR072304NIEHS NIH HHS F30 ES025626NIGMS NIH HHS T32 GM007753
Abstract
Although immune checkpoint inhibitors (ICIs), such as anti-programmed cell death protein-1 (PD-1), can deliver durable antitumor effects, most patients with cancer fail to respond. Recent studies suggest that ICI efficacy correlates with a higher load of tumor-specific neoantigens and development of vitiligo in patients with melanoma. Here, we report that patients with low melanoma neoantigen burdens who responded to ICI had tumors with higher expression of pigmentation-related genes. Moreover, expansion of peripheral blood CD8
Indexed as
Immune Checkpoint InhibitorsMelanomaAnimalsAntigens, NeoplasmEpitopesHumansMelanocytesMiceAntigens, NeoplasmEpitopesImmune Checkpoint Inhibitors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.